Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGFR | P43088 | 3/20 | 0.32 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25697454 | 0.85 | ACSS2 (0.30) | ACSS2 | |
| SCHEMBL25697148 | 0.82 | ACSS2 (0.33) | PTGFRACSS2KDM4EALDH1A1POLB | |
| SCHEMBL25697621 | 0.77 | ACSS2 (0.30) | ACSS2 | |
| SCHEMBL23958895 | 0.76 | PTGFR (0.39) | PTGFRACSS2KDM4EALDH1A1 | |
| SCHEMBL23958726 | 0.75 | CFTR (0.35) | PTGFRACSS2KDM4EALDH1A1MAPT | |
| SCHEMBL25697304 | 0.73 | ACSS2 (0.32) | PTGFRACSS2KDM4E | |
| SCHEMBL23958806 | 0.73 | CFTR (0.34) | PTGFRACSS2KDM4EALDH1A1POLB | |
| SCHEMBL25698074 | 0.73 | PTGFR (0.35) | PTGFRACSS2 | |
| SCHEMBL25697165 | 0.70 | IRAK4 (0.30) | — | |
| SCHEMBL25697681 | 0.70 | ACSS2 (0.31) | ACSS2KDM4EALDH1A1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203004-A1 | RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203004-A1 | RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES | ACE2, SIRT7, ACE | PTGFR 3859/4885ACSS2 1254/4885KDM4E 3733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.